| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2050 | Doxorubicin | Doxil | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1995 | Jul 1, 2013 | In Use | ||
| NA | Erlotinib | Tarceva | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| Q2058 | Obecabtagene autoleucel | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Jul 9, 2025 | In Use | ||
| N/A | Taletrectinib | IBTROZI | 272mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Yes | 2025 | In Use | |||
| C9148 | Teclistamab-cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| J8510 | Busulfan | Myleran | 2 mg | Chemotherapy | Alkylating Agent | Alkylsulfonate | Yes | 1954 | Jan 1, 2000 | In Use | ||
| Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
| S0119 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 4 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1991 | Jan 1, 2012 | In Use | ||
| J2425 | Palifermin | Kepivance | 50 mcg | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | No | 2004 | Jan 1, 2006 | In Use | ||
| NA | Cabozantinib | Cometriq | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| NA | Cabozantinib | Cabometyx | 60 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| NA | Ceritinib | Zykadia | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2014 | In Use | |||
| C9426 | Floxuridine | Floxuridine | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1970 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| Fruquintinib | Fruzaqla | 1mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2023 | In Use | ||||
| J9057 | Copanlisib | Aliqopa | 1mg | Chemotherapy | Enzyme Inhibitor | PI3K | No | 2017 | In Use | |||
| NA | Dasatinib | Sprycel | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
| Q5136 | Denosumab-bbdz | Jubbonti/Wyost | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2024 | Sep 11, 2024 | In Use | ||
| J8612 | Methotrexate (xatmep) | Xatmep | 2.5mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 2017 | Jun 10, 2024 | In Use | ||
| J9299 | Nivolumab | Opdivo | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan 1, 2016 | In Use | ||
| J2783 | Rasburicase | Elitek, Fasturtec | 0.5 mg | Ancillary Therapy | Metabolic Agent | Enzyme | No | 2002 | Jan 1, 2004 | In Use | ||
| J9356 | Trastuzumab and Hyaluronidase-oysk | Herceptin hylecta | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Jul 1, 2019 | In Use | ||
| J9274 | Tebentafusp-tebn | Kimmtrak | 1mcg | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | No | 2022 | Sep 27, 2022 | In Use | ||
| J0893 | Decitabine (Sun Pharma) | Decitabine | 1mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2014 | Dec 21, 2022 | In Use | ||
| J9002 | Doxorubicin | Doxil | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1995 | Jan 1, 2013 | Dec 31, 2013 | No Longer Used | |
| NA | Duvelisib | Copiktra | 15mg, 25mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2018 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home